ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients (Q30248761)

13 June 2017

1 reference

title

ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients (English)

1 reference

13 June 2017

Divi Cornec

1 reference

13 June 2017

Emilie Cornec-Le Gall

series ordinal

1 reference

13 June 2017

Fernando C Fervenza

series ordinal

1 reference

13 June 2017

Ulrich Specks

series ordinal

1 reference

13 June 2017

language of work or name

English

0 references

publication date

28 July 2016

1 reference

Nature Reviews Rheumatology

13 June 2017

published in

1 reference

13 June 2017

1 reference

13 June 2017

1 reference

13 June 2017

page(s)

570-579

1 reference

Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology?

13 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Wegener's autoantigen decoded

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

EULAR recommendations for the management of primary small and medium vessel vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

31 March 2020

12 December 2020

The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis)

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Key advances in the clinical approach to ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Diagnosis and/or classification of vasculitis: different?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Inhibitors and Antibody Fragments as Potential Anti-Inflammatory Therapeutics Targeting Neutrophil Proteinase 3 in Human Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Proteinase 3, the Wegener autoantigen, is externalized during neutrophil apoptosis: evidence for a functional association with phospholipid scramblase 1 and interference with macrophage phagocytosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Membrane surface proteinase 3 expression and intracytoplasmic immunoglobulin on neutrophils from patients with ANCA-associated vasculitides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Dysregulation of autoantigen genes in ANCA-associated vasculitis involves alternative transcripts and new protein synthesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Netting neutrophils in autoimmune small-vessel vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Properties of circulating IgA molecules in Henoch-Schönlein purpura nephritis with focus on neutrophil cytoplasmic antigen IgA binding (IgA-ANCA): new insight into a debated issue. Italian Group of Renal Immunopathology Collaborative Study on Henoch

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Pauci-immune crescentic glomerulonephritis associated with ANCA of IgA class

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasmic antibodies against myeloperoxidase, proteinase 3, elastase, cathepsin G and lactoferrin in Japanese patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Seroprevalence and disease association of antineutrophil cytoplasmic autoantibodies and antigens in HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Vasculitis: Will LAMP enlighten us about ANCA-associated vasculitis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Relevance of the mouse model as a therapeutic approach for neutrophil proteinase 3-associated human diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Differences between human proteinase 3 and neutrophil elastase and their murine homologues are relevant for murine model experiments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Discrimination and variable impact of ANCA binding to different surface epitopes on proteinase 3, the Wegener’s autoantigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Does autoantigen complementarity underlie PR3-ANCA AAV?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Alpha1‐antitrypsin deficiency–related alleles Z and S and the risk of Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

TheSEM6A6Locus Is Not Associated With Granulomatosis With Polyangiitis or Other Forms of Antineutrophil Cytoplasmic Antibody-Associated Vasculitides in Europeans: Comment on the Article by Xie et al

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Genetically distinct subsets within ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Genetic variants in ANCA-associated vasculitis: a meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ANCA-negative pauci-immune crescentic glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Heart transplantation in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Etanercept plus standard therapy for Wegener's granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of rem

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Can antineutrophil cytoplasmic antibody levels be used to inform treatment of pauci-immune vasculitis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Current and emerging techniques for ANCA detection in vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Accurate relapse prediction in ANCA-associated vasculitis-the search for the Holy Grail

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Efficacy of remission-induction regimens for ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Damage assessment in ANCA-associated vasculitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Long-term patient survival in ANCA-associated vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Histopathologic classification of ANCA-associated glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

Epidemiology of vasculitis in Europe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2016.123

The long-term outcomes of systemic vasculitis.

31 March 2020

1 reference

12 December 2020

A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis

1 reference

12 December 2020

Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis

1 reference

12 December 2020

A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis

1 reference

12 December 2020

Proteinase 3, Wegener's autoantigen: from gene to antigen

1 reference

12 December 2020

Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils

1 reference

12 December 2020

Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001.

1 reference

12 December 2020

The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

1 reference

12 December 2020

Wegener's granulomatosis: studies in eighteen patients and a review of the literature

1 reference

12 December 2020

ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center

1 reference

12 December 2020

Presence of proteinase 3 in secretory vesicles: evidence of a novel, highly mobilizable intracellular pool distinct from azurophil granules

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2016.123

1 reference

Dimensions Publication ID

13 June 2017

1024545012

0 references

1 reference